
Medfacto announced on the 16th that domestic and international attention has been focused on its anticancer drug candidate 'MP010' after its preclinical results were selected as a cover article in the November issue of 'Cancer Cell,' an academic journal with the world’s highest authority. Medfacto is pursuing a strategy to make all-out efforts for the early technology transfer of MP010.
Medfacto announced on the 10th that it has elucidated an innovative technology whereby MP010 prevents the recurrence of primary cancer through in vivo immune memory and even prevents other non-primary cancers (secondary cancers). These research results were published in Cancer Cell, which has an Impact Factor (IF) of 56.1. Cancer Cell is considered an academic journal with influence on par with 'NATURE' (Nature, IF=56.1), 'Science' (Science, IF=47.3), and others.
Medfacto’s MP010 is a dual-strategy anticancer drug candidate that selectively binds to 'Extra Domain-B Fibronectin' (EDB-FN), which is overexpressed in the tumor microenvironment (TME), while simultaneously targeting 'TGF-β' (Transforming Growth Factor), which induces immune evasion in cancer.
In preclinical results for MP010, it recorded a cure rate of 75–87.5% and a long-term survival rate of 87.5% in three animal models of highly aggressive pancreatic cancer with low responsiveness. It also showed a protective effect blocking tumor development in more than 80% of individuals when the same cancer cells or other cancer cells, such as lung cancer or bladder cancer, were transplanted after complete remission.
Medfacto participated in 'BioEurope,' held in Germany from the 9th to the 11th, and reported that MP010 received significant interest from numerous multinational pharmaceutical companies.
A Medfacto official stated, "As news of the Cancer Cell paper publication reached the BioEurope site, many global pharmaceutical company officials and overseas researchers congratulated us and showed interest in MP010’s mechanism of action and clinical plans," adding that "numerous consultations regarding joint research, such as combination therapy with antibody-drug conjugates (ADCs), were also conducted."
Medfacto plans to prepare the Investigational New Drug (IND) application for MP010 while simultaneously pushing forward with early technology transfer.
A Medfacto official stated, "Publication in a high-impact international academic journal signifies that it has passed rigorous validation of technical capability, and is sometimes called a 'guaranteed check' for technology transfer in the industry," adding that "after the publication of the MP010 preclinical paper, more than dozens of inquiries regarding clinical trials were received from overseas biotech companies, research institutes, and patients with pancreatic cancer and their caregivers." The official further added, "The content of the paper was covered as major news by North American and European media, and inquiry requests from overseas science-specialized media continue to pour in."